
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$1.97
−US$0.055 · -2.72%
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
收盘时
US$1.97
−US$0.055 · -2.72%
盘后
US$1.97
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
日内区间
当前US$1.97
52周区间
当前US$1.97
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
59
合理估值
情绪
52
多空交织
风险
53
风险偏高
动量
34
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
日内区间
当前US$1.97
52周区间
当前US$1.97
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 5757万 USD | 6638.2万 USD | 6518.3万 USD | 1.07亿 USD | 9666.9万 USD |
| 销货成本 | 2075.2万 USD | 2055.1万 USD | 1612.9万 USD | 4076.7万 USD | 4638.6万 USD |
| 毛利 | 3681.8万 USD | 4583.1万 USD | 4905.4万 USD | 6663.2万 USD | 5028.3万 USD |
| 研究与开发 | — | 132.6万 USD | 276.9万 USD | 409.5万 USD | 1266.2万 USD |
| 销售、一般及管理费用 | 4264.1万 USD | 3828.5万 USD | 4203.7万 USD | 7007.8万 USD | 6988万 USD |
| 营业费用 | 4513.3万 USD | 5365.8万 USD | 5064.5万 USD | 8369.7万 USD | 1.6亿 USD |
| 利息收入 | — | — | — | — | 1.4万 USD |
| 利息支出 | −189.5万 USD | 370.3万 USD | 479.2万 USD | 496.3万 USD | 1.47亿 USD |
| 折旧和摊销 | 393万 USD | 537.7万 USD | 672.5万 USD | 881.5万 USD | 1014.6万 USD |
| 营业利润 | −831.5万 USD | −782.7万 USD | −159.1万 USD | −1706.5万 USD | −1.1亿 USD |
| 净利润 | −1425.2万 USD | −1356.2万 USD | −1584.4万 USD | −1705.1万 USD | −1.09亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年1月6日 | 1:20 | — | — |
股票拆分 | 2020年12月9日 | 1:10 | — | — |
股票拆分 | 2018年8月13日 | 1:20 | — | — |
股票拆分 | 2017年8月29日 | 1:20 | — | — |
股票拆分 | 2016年10月28日 | 1:12 | — | — |
股票拆分 | 2016年7月1日 | 1:12 | — | — |
已生效 2023年1月6日
1:20
已生效 2020年12月9日
1:10
已生效 2018年8月13日
1:20
已生效 2017年8月29日
1:20
已生效 2016年10月28日
1:12
已生效 2016年7月1日
1:12
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI38.7万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF21.1万0.00%954亿 USD0.05%US$233.52-0.63%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.27万0.00%455.91亿 USD0.17%US$84.43-0.01%
Dimensional - US Core Equity 2 ETFDFAC1.18万0.00%885.96亿 USD0.21%US$45.31-0.04%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.11万0.00%61.81亿 USD0.26%US$68.32+0.06%
Dimensional - US Sustainability Core 1 ETFDFSU9730.130.00%23.92亿 USD0.15%US$48.13+0.04%
Dimensional - US Small Cap ETFDFAS8914.050.00%338.69亿 USD0.31%US$78.17-0.23%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR
Dimensional - US Core Equity 2 ETFDFAC
U.S. Vector Equity Portfolio ETF Class SharesDXUV
Dimensional - US Sustainability Core 1 ETFDFSU
Dimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。